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Huntington’s disease (HD) is a monogenic autosomal dominant, fatal disorder due to CAG
trinucleotide expansion in exon 1 of the HD gene (HTT) (The Huntington’s Disease Collaborative
Research Group, 1993; Figure 1A). Nowadays, there is no cure or effective treatment for the disease
which presents with motor, cognitive and psychiatric dysfunction. Although typically conceived
as a “neurodegenerative disease,” mainly affecting the GABAergic medium-sized spiny neurons
(MSN) of the striatum and deep layers of the cortex (Rosas et al., 2003), an increasing body of
evidence has surfaced indicating that abnormal neurodevelopment might also have a crucial role
in HD (Mehler and Gokhan, 2000, 2001; Humbert, 2010). Neurodegenerative diseases have been
classically defined as chronic and progressive disorders of the nervous system affecting neurologic
and behavioral functions, which start with specific biochemical changes that ultimately lead to
distinct histopathologic and clinical syndromes. On the contrary, neurodevelopmental disorders
result from an anomaly of brain maturation, during fetal or early postnatal life, which is postulated
to alter the structure and/or function of neuronal and synaptic populations (Harrison, 1995).
This opinion piece discusses the existing evidences from HD patients and HD model systems
for a neurodevelopmental component to the neurodegenerative processes of Huntington’s Disease
pathophysiology.
The first and most striking observations come from multi-national neuropathological and
neuroimaging studies of prodromal HD, reporting clear brain changes decades prior to onset of
disease: specifically, smaller head circumference (Lee et al., 2012), caudate and putamen atrophy
(Nopoulos et al., 2007; Paulsen et al., 2010), striatal and cortical white matter abnormalities
including increased density of oligodendrocytes (Gómez-Tortosa et al., 2001) and cortical thinning
(Nopoulos et al., 2007) were described. Moreover, subtle but significant defects in cognitive
(Solomon et al., 2007), behavioral (Duff et al., 2007), and motor function (Hinton et al., 2007) have
been identified in prodromal HD subjects long before a clinical diagnosis. While these observations
might be linked to early neuronal degeneration, the other plausible interpretation is that they
represent manifestations of subtle altered development that prime specific areas and neuronal
subpopulations of the brain to later catastrophic consequences (Figure 1).
Further indications come from studies of mouse models with inactivation of the HD orthologue
gene Htt. Huntingtin protein, in fact, is expressed in all cell types of the body, at all developmental
stages and it has crucial roles during development and neurogenesis (Figure 1B). Parallel
studies have shown that complete lack of huntingtin in mice results in embryonic lethality
with developmental arrest just post gastrulation (Duyao et al., 1995; Zeitlin et al., 1995), while
severe reduction of huntingtin levels in heterozygous, Htt hypomorphic mice or Htt conditional
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knock-out neuronal subpopulations manifests in abnormal
brain development, cognitive and motor abnormalities (Nasir
et al., 1995; White et al., 1997; Auerbach et al., 2001; Godin
et al., 2010). Given this key role of wild-type huntingtin
during development, it is not surprising that studies on genetic
engineered mice expressing Htt CAG-expansion pathogenic
mutations show subtle molecular and structural deficits that
portend altered developmental processes and precede the
occurrence of neurological symptoms and signs of cell death
(Luthi-Carter et al., 2000; Wheeler et al., 2000; Fossale et al.,
2011). Specifically, even in Hdh knock-in mice, representing a
faithful genetic replica of the human HD mutation [expressing
full-length mutant huntingtin at endogenous levels from the
native promoter at the Htt locus], although usually presenting
milder molecular and behavioral phenotypes compared to HD
transgenic and fragment lines, one single copy of the mutant Htt
allele is sufficient to cause nuclear accumulation of full-length
mutant huntingtin in MSN as early as 3 weeks of age (Wheeler
et al., 2000), molecular changes in pathways related to energy
metabolism and cAMP levels, RNA metabolism (Gines et al.,
2003) and measurable transcription/translation dysfunctions
(Fossale et al., 2011) at 3 and 10 weeks of age, well before the
onset of any overt pathological alteration. Strikingly, in the
same Hdh Q111 knock-in HD mouse model, deregulation of the
temporal and spatial profiles of striatal neurogenesis [delayed
cell cycle exit and transient aberrant expression of pluripotency
markers in MSN-generating neural stem cells] (Molero
et al., 2009) may expose striatal precursors to inappropriate
molecular cues driving them into aberrant programs of
neuronal differentiation, thus reinforcing the notion that altered
neurodevelopmentmight forecast laterMSN susceptibility in HD
(Figure 1C).
Additional consistent observations emerged from studies
using mouse embryonic stem cells and neural committed
progenitors bearing Htt CAG-expansion mutations (Jacobsen
et al., 2011; Conforti et al., 2013; Biagioli et al., 2015) as well
as patient-derived induced pluripotent stem cells (iPSCs)
(The HD iPSC Consortium, 2012), showing measurable
molecular differences and a series of expanded CAG-associated
phenotypes that point toward a central role of wild-type and
mutant huntingtin in signal transduction, axonal guidance,
synaptic transmission and neurodevelopment. Specifically,
unbiased “- omics” analyses, probing transcriptomic, chromatin
modifications and DNA methylation status in these cells
and their neuronal derivatives, support the hypothesis that
wild-type and mutant huntingtin might affect key chromatin
regulators such as DNA and histone methyl transferases, and
demethylases [Polycomb Repressive Complex 2 (PRC2), Mixed
Lineage Leukemia 1–4, JARID1, REST, HYPB-SETD2] (Lee
et al., 2013; Ng et al., 2013; Biagioli et al., 2015). In fact, a
growing body of evidence suggests that alterations of epigenetic
modifications constitute a basic molecular mechanism caused
by the HD mutation and responsible for early features of
the pathological process. Strikingly, most of these epigenetic
regulators, i.e., Polycomb Complexes, but also other histone
post-transcriptional modifications enzymes, have important
roles during transition from pluripotency to differentiation and
neural development, in particular (Jepsen et al., 2007). While
FIGURE 1 | CAG expansion in the human HTT gene leads to
Huntington’s Disease (HD): possible contribution of altered non-coding
RNA transcription and aberrant developmental processes are
described. (A) Top pie charts report the proportion of coding and noncoding
RNAs in the human genome (Alexander et al., 2010). Highlighted in the coding
portion of the genome, the Huntington’s Disease gene (HTT ). Wild type or
expanded CAG lengths are indicated by sepia and gray colors, respectively.
Bottom pie charts summarize the relative contribution of single classes of
non-coding RNAs (Baker, 2011) to normal (sepia) or diseased (gray) organism
physiology. The contribution of non-coding RNA transcription to HD process is
still not fully dissected. (B) Schematic representation of human development at
different stages [blastocyst (5 days) and 25 days embryos, 100 days and 5
months fetuses and adult organism] is shown. Normal (sepia) and mutant
huntingtin [expanded HTT gene] (grayscale) expression is found in the whole
organism at any given developmental stage (MacDonald et al., 2003; Gusella
and MacDonald, 2006). Molecular mechanisms (miRNAs, lncRNAs, alterative
splicing, histone modifications and chromatin remodeling) acting since
conception in the organism bearing the mutation are represented by the gray
area. (C) A simplified representation of HD brain development is shown.
Developmental stages as in (B). Different color’s shades denote specific brain
regions such as telencephalon, diencephalon, midbrain, and hindbrain which
develop differently to originate adult brain structures. Light gray lines across
the head designate coronal sections unveiling inner brain organization, while
puzzle pieces represent various cell types constituting each brain district. It is
evident that the presence of mutant huntingtin (expanded HTT gene) places
any cell of the organism—and of the brain in particular—in a “different
biological state” with subtle cellular and tissue development alterations that
culminate in the overt symptoms appearing in adult life. The changes induced
by the expression of CAG-repeat HTT expansion compromise
MSN-generating stem cells specification and prime MSN to adult neuronal
degeneration (Molero et al., 2009; Humbert, 2010).
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the exact mechanisms of this “huntingtin chromatin function”
are not entirely known, some evidence has accumulated
suggesting that wild-type and CAG-expanded huntingtin may
interact, directly or indirectly, with epigenetic co-regulators
and alter their activity (Seong et al., 2010). Interestingly, the
DNA methylation pattern of several promoter regions of
genes involved with pluripotency and neural differentiation
(Sox2, Pax6, Nes) was found significantly reduced in presence
of mutant huntingtin (Ng et al., 2013), while the histone
methylation status of a class of developmentally-regulated
bivalent promoters associated with “Regulation of Neurogenesis”
and “Stress Signaling and Apoptosis” was altered following the
expression of CAG-expanded Htt alleles (Biagioli et al., 2015).
Thus, huntingtin protein might subtly but consistently alter
different aspects of chromatin regulation and transcription
during neural development and specification, explaining
the pleiotropic, subtle yet deleterious, effects of mutant
huntingtin observed throughout the life of an HD individual
(Figures 1B,C).
Parallel to alterations in the coding portion of the genome,
a growing number of studies is recently showing deregulation
of different classes of non-coding RNAs (ncRNAs)—microRNAs
(miRNAs), long non-coding RNAs (lncRNAs), piwi-interacting
RNAs (piRNAs), circular RNAs (circRNAs)—suggesting that they
may have a relevant impact on disease onset/progression. A large
percentage of ncRNAs physically interact with various chromatin
regulatory proteins, including PRC2, and other “readers/writers,
and erasers” of chromatin modifications, thus activating
or repressing gene expression via a chromatin recruitment
mechanism. The first, intriguing example of such regulatory
network is the mammalian X-chromosome inactivation, where
the finely regulated expression of Xist lncRNA is able to
recruit PRC2 to the specific genomic location of the silenced
X chromosome to mediate transcriptional repression. Recently,
systematic studies exploring ncRNA function have shown
their involvement in many biological processes also related to
embryonic development and neurogenesis (Qureshi and Mehler,
2012, Sauvageau et al., 2013). Particularly, several miRNAs, but
also lncRNAs have been reported to be enriched in the brain
and have key roles during transition from neural commitment
to terminal differentiation (Makeyev et al., 2007; Sauvageau
et al., 2013). Importantly, miRNAs might also target neuronal-
specific transcriptional regulators (i.e., REST and co-REST) as
well as brain-enriched alternative-splicing factors, thus affecting
synaptic activity and neuronal function (Makeyev et al., 2007;
Packer et al., 2008). Mutant huntingtin expression has been
correlated with alterations in REST cellular localization and
dysregulation of REST-regulated miRNAs (miR-9 and miR-
124) levels (Packer et al., 2008). Specifically, miR-9 and miR-
124 levels were shown to be reduced in the cortical areas of
HD post mortem brains where genes related to neurogenesis
were highly overrepresented (Hodges et al., 2006). Moreover,
a recent genome-wide screen of miRNAs in post mortem
brains highlighted miRNAs that were differentially expressed
between normal and HD subjects (Hoss et al., 2014). The vast
majority of these miRNAs are highly connected with HOX
clusters, a well-studied family of transcription factors, involved
in early brain development, contributing to anterior-posterior
positional establishment. HOX genes and HOX-related miRNAs
are tightly regulated by PRC2 proteins and are found to be altered
following mutant huntingtin expression (Seong et al., 2010).
Although the role of development-specific miRNAs and HOX
genes in the adult HD brain is still unclear, one interpretation
might suggest aberrant brain development following mutant
huntingtin expression, while, a second plausible explanation
might invoke a reactivation of developmental programs in
the later phases of HD degenerative process where surviving
and neurogenic hints try to counteract generalized neuronal
loss.
MiRNAs, however, are not the only class of ncRNAs with
developmental potential to be dysregulated in HD. Several
additional studies, in fact, report altered expression levels of
known lncRNAs TUG1, NEAT1, MEG3, and DGCR5 in the
brains of HD patients (Johnson, 2012). MEG3, in particular,
is reported to be a REST target with a dynamic expression
during development of the nervous system and associated with
PRC2 chromatin regulator, thus supporting a role for chromatin
regulation, non-coding transcription and neurodevelopment in
HD pathogenesis.
Other classes of ncRNA (pi-RNAs and circRNAs), associated
with chromatin remodeling factors and epigenetic modulators,
have a clear role during neural development and differentiation,
however their regulation upon expression of mutant huntingtin
has not been analyzed yet.
The analysis of non-coding RNA transcription and its
interplay with chromatin regulation in the context of human
neurological disease presents several challenges especially related
to the complexity of ncRNAs in the brain. In fact, the
annotation, identification and functional characterization of
ncRNAs continue to be puzzling because of the lack of a
complete understanding of functional domains, their generally
low expression levels, and the poor knowledge of their regulatory
regions (Esteller, 2011). International initiatives such as the
Encyclopedia of DNA Elements (ENCODE) or the generation
of knock-out mice for specific ncRNAs (Sauvageau et al., 2013,
Goff et al., 2015) represent the first effort to understand the
functional relevance of ncRNAs in the organism (and brain)
physiology and disease. Additional studies in this direction as
well as new and powerful genomic and bioinformatic tools
will be crucial to dissect the complexity of ncRNA brain
transcriptome to understand how the interaction between
epigenome and transcriptome will contribute to disease onset
and progression and shed light on possible new paths to
therapeutic intervention.
In conclusion, it’s time to rethink the simple view of
Huntington’s Disease as a merely neurodegenerative disorder
to include the idea that expression of the single copy of the
CAG-expanded HTT allele (Figure 1A) is also sufficient to
subtly alter development from conception. The “HD organism”
is, at any developmental time point, different from the “not-
HD counterpart” (Figures 1B,C). Like in a puzzle where the
HTT-CAG mutation forces pieces to fit where they do not
belong, similarly subtle developmental differences may give
rise to a different panoply of adequately functioning units
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which may last for a long time but ultimately not allow the
same flexibility with aging, thus aberrant neurodevelopment
might lead to disorganization and dysconnectivity of neurons
and subsequent susceptibility to neurodegenerative processes
(Figures 1B,C). Essential corollaries of this model are not
only new approaches to the understanding of the altered
pathologic process, but also new strategies of therapeutic
intervention/prevention. In fact, the recent identification of
genetic factors that are able to modify the age of onset of HD
patients, indicate that the HD pathologic process is modifiable
prior to clinical diagnosis (Genetic Modifiers of Huntington’s
Disease (GeM-HD) Consortium, 2015), thus representing a
proof-of-principle of a strategy that is predicated upon the idea
that intervening before onset of clinical signs is likely to be most
effective to finally ameliorate patients quality of life and/or life
expectancy.
AUTHOR CONTRIBUTIONS
EK made substantial contributions to conception and design
of the work and participated in drafting the manuscript; MB
conceived and supervised the project and wrote the paper.
Authors read and gave final approval of the manuscript version
version to be submitted.
ACKNOWLEDGMENTS
We thank Dr. Marcy MacDonald (Massachusetts General
Hospital, Harvard Medical School, Boston U.S.A.) for critical
reading of the manuscript and useful suggestions. This work was
supported by CIBIO-University of Trento (Italy) start-up and
by the Huntington’s Society of Canada “New pathways” research
grants to MB.
REFERENCES
Alexander, R. P., Fang, G., Rozowsky, J., Snyder, M., and Gerstein, M. B. (2010).
Annotating non-coding regions of the genome. Nat. Rev. Genet. 11, 559–571
doi: 10.1038/nrg2814
Auerbach, W., Hurlbert, M. S., Hilditch-Maguire, P., Wadghiri, Y. Z., Wheeler,
V. C., Cohen, S. I., et al. (2001). The HD mutation causes progressive lethal
neurological disease inmice expressing reduced levels of huntingtin.Hum.Mol.
Genet. 10, 2515–2523. doi: 10.1093/hmg/10.22.2515
Baker, M. (2011). Long noncoding RNAs: the search for function. Nat. Methods 8,
379–383. doi: 10.1038/nmeth0511-379
Biagioli, M., Ferrari, F., Mendenhall, E. M., Zhang, Y., Erdin, S., Vijayvargia, R.,
et al. (2015). HTT CAG repeat expansion confers pleiotropic gains of mutant
huntingtin function in chromatin regulation.Hum. Mol. Genet. 24, 2442–2457.
doi: 10.1093/hmg/ddv006
Conforti, P., Camnasio, S., Mutti, C., Valenza, M., Thompson, M., Fossale, E.,
et al. (2013). Lack of huntingtin promotes neural stem cells differentiation into
glial cells while neurons expressing huntingtin with expanded polyglutamine
tracts undergo cell death. Neurobiol. Dis. 50, 160–170. doi: 10.1016/j.nbd.2012.
10.015
Duff, K., Paulsen, J. S., Beglinger, L. J., Langbehn, D. R., Stout, J. C., and The
Predict-HD Investigators of the Huntington Study Group (2007). Psychiatric
symptoms in Huntington’s Disease before diagnosis: the Predict-HD Study.
Biol. Psychiatry 62, 1341–1346. doi: 10.1016/j.biopsych.2006.11.034
Duyao, M. P., Auerbach, A. B., Ryan, A., Persichetti, F., Barnes, G. T., McNeil, S.
M., et al. (1995). Inactivation of the mouse Huntington’s disease gene homolog
Hdh. Science 269, 407–410. doi: 10.1126/science.7618107
Esteller, M. (2011). Non-coding RNAs in human disease. Nat. Rev. Genet. 12,
861–874. doi: 10.1038/nrg3074
Fossale, E., Seong, I. S., Coser, K. R., Shioda, T., Kohane, I. S., Wheeler, V. C.,
et al. (2011). Differential effects of the Huntington’s disease CAG mutation in
striatum and cerebellum are quantitative not qualitative. Hum. Mol. Genet. 20,
4258–4267. doi: 10.1093/hmg/ddr355
Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium (2015).
Identification of genetic factors that modify clinical onset of Huntington’s
Disease. Cell 162, 516–526. doi: 10.1016/j.cell.2015.07.003
Gines, S., Seong, I. S., Fossale, E., Ivanova, E., Trettel, F., Gusella, J. F., et al.
(2003). Specific progressive cAMP reduction implicates energy deficit in
presymptomatic Huntington’s disease knock-in mice. Hum. Mol. Genet. 12,
497–508. doi: 10.1093/hmg/ddg046
Godin, J. D., Poizat, G., Hickey, M. A., Maschat, F., and Humbert, S. (2010).
Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity
in Huntington’s disease. EMBO J. 29, 2433–2445. doi: 10.1038/emboj.2010.117
Goff, L. A., Groff, A. F., Sauvageau, M., Trayes-Gibson, Z., Sanchez-Gomez, D.
B., Morse, M., et al. (2015). Spatiotemporal expression and transcriptional
perturbations by long noncoding RNAs in the mouse brain. Proc. Natl. Acad.
Sci. U.S.A. 112, 6855–6862. doi: 10.1073/pnas.1411263112
Gómez-Tortosa, E., MacDonald, M. E., Friend, J. C., Taylor, S. A. M., and
Weiler, L. J., Adrienne Cupples, L., et al. (2001). Quantitative neuropathological
changes in presymptomatic Huntington’s disease. Ann. Neurol. 49, 29–34. doi:
10.1002/1531-8249(200101)49:1<29::AID-ANA7>3.0.CO;2-B
Gusella, J. F., and MacDonald, M. E. (2006). Huntington’s disease: seeing the
pathogenic process through a genetic lens. Trends Biochem. Sci. 31, 533–540.
doi: 10.1016/j.tibs.2006.06.009
Harrison, P. J. (1995). On the neuropathology of schizophrenia and its dementia:
neurodevelopmental, neurodegenerative, or both? Neurodegeneration 4, 1–12.
Hinton, S. C., Paulsen, J. S., Hoffmann, R. G., Reynolds, N. C., Zimbelman,
J. L., and Rao, S. M. (2007). Motor timing variability increases in
preclinical Huntington’s disease patients as estimated onset of motor
symptoms approaches. J. Int. Neuropsychol. Soc. 13, 539–543. doi:
10.1017/S1355617707070671
Hodges, A., Strand, A. D., Aragaki, A. K., Kuhn, A., Sengstag, T., Hughes, G., et al.
(2006). Regional and cellular gene expression changes in human Huntington’s
disease brain. Hum. Mol. Genet. 15, 965–977. doi: 10.1093/hmg/ddl013
Hoss, A. G., Kartha, V. K., Dong, X., Latourelle, J. C., Dumitriu, A., Hadzi,
T. C., et al. (2014). MicroRNAs located in the Hox Gene Clusters are
implicated inHuntington’s Disease pathogenesis. PLoSGenet. 10:e1004188. doi:
10.1371/journal.pgen.1004188
Humbert, S. (2010). Is Huntington disease a developmental disorder? EMBO Rep.
11, 899. doi: 10.1038/embor.2010.182
Jacobsen, J. C., Gregory, G. C., Woda, J. M., Thompson, M. N., Coser, K. R.,
Murthy, V., et al. (2011). HD CAG-correlated gene expression changes support
a simple dominant gain of function. Hum. Mol. Genet. 20, 2846–2860. doi:
10.1093/hmg/ddr195
Jepsen, K., Solum, D., Zhou, T., McEvilly, R. J., Kim, H.-J., Glass, C. K., et al. (2007).
SMRT-mediated repression of an H3K27 demethylase in progression from
neural stem cell to neuron. Nature 450, 415–419. doi: 10.1038/nature06270
Johnson, R. (2012). Long non-coding RNAs in Huntington’s disease
neurodegeneration. Neurobiol. Dis. 46, 245–254. doi: 10.1016/j.nbd.2011.
12.006
Lee, J., Hwang, Y. J., Kim, K. Y., Kowall, N. W., and Ryu, H. (2013). Epigenetic
mechanisms of neurodegeneration in Huntington’s Disease. Neurotherapeutics
10, 664–676. doi: 10.1007/s13311-013-0206-5
Lee, J. K., Mathews, K., Schlaggar, B., Perlmutter, J., Paulsen, J. S., Epping, E.,
et al. (2012). Measures of growth in children at risk for Huntington disease.
Neurology 79, 668–674. doi: 10.1212/WNL.0b013e3182648b65
Luthi-Carter, R., Strand, A., Peters, N. L., Solano, S. M., Hollingsworth, Z. R.,
Menon, A. S., et al. (2000). Decreased expression of striatal signaling genes in
a mouse model of Huntington’s disease. Hum. Mol. Genet. 9, 1259–1271. doi:
10.1093/hmg/9.9.1259
Frontiers in Neuroscience | www.frontiersin.org 4 January 2016 | Volume 9 | Article 509
Kerschbamer and Biagioli Huntington’s Disease as Neurodevelopmental Disorder
MacDonald, M. E., Gines, S., Gusella, J. F., andWheeler, V. C. (2003). Huntington’s
Disease. Neuro Mol. Med. 4, 7–20. doi: 10.1385/NMM:4:1-2:7
Makeyev, E. V., Zhang, J., Carrasco, M. A., and Maniatis, T. (2007).
The MicroRNA miR-124 promotes neuronal differentiation by triggering
brain-specific alternative Pre-mRNA Splicing. Mol. Cell 27, 435–448. doi:
10.1016/j.molcel.2007.07.015
Mehler, M. F., and Gokhan, S. (2000). Mechanisms underlying neural cell death in
neurodegenerative diseases: alterations of a developmentally-mediated cellular
rheostat. Trends Neurosci. 23, 599–605. doi: 10.1016/S0166-2236(00)01705-7
Mehler, M. F., and Gokhan, S. (2001). Developmental mechanisms in the
pathogenesis of neurodegenerative diseases. Prog. Neurobiol. 63, 337–363. doi:
10.1016/S0301-0082(00)00052-6
Molero, A. E., Gokhan, S., Gonzalez, S., Feig, J. L., Alexandre, L. C., and
Mehler, M. F. (2009). Impairment of developmental stem cell-mediated
striatal neurogenesis and pluripotency genes in a knock-in model of
Huntington’s disease. Proc. Natl. Acad. Sci. U.S.A. 106, 21900–21905. doi:
10.1073/pnas.0912171106
Nasir, J., Floresco, S. B., O’Kusky, J. R., Diewert, V. M., Richman, J. M.,
Zeisler, J., et al. (1995). Targeted disruption of the Huntington’s disease gene
results in embryonic lethality and behavioral and morphological changes in
heterozygotes. Cell 81, 811–823.
Ng, C. W., Yildirim, F., Yap, Y. S., Dalin, S., Matthews, B. J., Velez, P. J., et al.
(2013). Extensive changes in DNA methylation are associated with expression
of mutant huntingtin. Proc. Natl. Acad. Sci. U.S.A. 110, 2354–2359. doi:
10.1073/pnas.1221292110
Nopoulos, P., Magnotta, V. A., Mikos, A., Paulson, H., Andreasen, N.
C., and Paulsen, J. S. (2007). Morphology of the cerebral cortex in
preclinical Huntington’s disease. Am. J. Psychiatry 164, 1428–1434. doi:
10.1176/appi.ajp.2007.06081266
Packer, A. N., Xing, Y., Harper, S. Q., Jones, L., and Davidson, B. L. (2008).
The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and
is downregulated in Huntington’s Disease. J. Neurosci. 28, 14341–14346. doi:
10.1523/JNEUROSCI.2390-08.2008
Paulsen, J. S., Nopoulos, P. C., Aylward, E., Ross, C. A., Johnson, H.,
Magnotta, V. A., et al. (2010). Striatal and white matter predictors of
estimated diagnosis for Huntington disease. Brain Res. Bull. 82, 201–207. doi:
10.1016/j.brainresbull.2010.04.003
Qureshi, I. A., and Mehler, M. F. (2012). Emerging roles of non-coding RNAs in
brain evolution, development, plasticity and disease. Nat. Rev. Neurosci. 13,
528–541. doi: 10.1038/nrn3234
Rosas, H. D., Koroshetz, W. J., Chen, Y. I., Skeuse, C., Vangel, M., Cudkowicz,
M. E., et al. (2003). Evidence for more widespread cerebral pathology in early
HD: an MRI-based morphometric analysis. Neurology 60, 1615–1620. doi:
10.1212/01.WNL.0000065888.88988.6E
Sauvageau,M., Goff, L. A., Lodato, S., Bonev, B., Groff, A. F., Gerhardinger, C., et al.
(2013). Multiple knockout mouse models reveal lincRNAs are required for life
and brain development. Elife 2, 1–24. doi: 10.7554/eLife.01749
Seong, I. S., Woda, J. M., Song, J.-J., Lloret, A., Abeyrathne, P. D., Woo, C. J.,
et al. (2010). Huntingtin facilitates polycomb repressive complex 2. Hum. Mol.
Genet. 19, 573–583. doi: 10.1093/hmg/ddp524
Solomon, A. C., Stout, J. C., Johnson, S. A., Langbehn, D. R., Aylward,
E. H., Brandt, J., et al. (2007). Verbal episodic memory declines prior
to diagnosis in huntington’s disease. Neuropsychologia 45, 1767–1776. doi:
10.1016/j.neuropsychologia.2006.12.015
The HD iPSC Consortium (2012). Induced pluripotent stem cells from patients
with huntington’s disease show cag-repeat-expansion-associated phenotypes.
Cell Stem Cell 11, 264–278. doi: 10.1016/j.stem.2012.04.027
The Huntington’s Disease Collaborative Research Group (1993). A novel gene
containing a trinucleotide repeat that is expanded and unstable onHuntington’s
disease chromosomes. Cell 72, 971–983.
Wheeler, V. C., White, J. K., Gutekunst, C. A., Vrbanac, V., Weaver, M., Li,
X. J., et al. (2000). Long glutamine tracts cause nuclear localization of a
novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and
HdhQ111 knock-in mice. Hum. Mol. Genet. 9, 503–513. doi: 10.1093/hmg/
9.4.503
White, J. K., Auerbach, W., Duyao, M. P., Vonsattel, J.-P., Gusella, J. F., Joyner, A.
L., et al. (1997). Huntingtin is required for neurogenesis and is not impaired
by the Huntington’s disease CAG expansion. Nat. Genet. 17, 404–410. doi:
10.1038/ng1297-404
Zeitlin, S., Liu, J.-P., Chapman, D. L., Papaioannou, V. E., and Efstratiadis, A.
(1995). Increased apoptosis and early embryonic lethality in mice nullizygous
for the Huntington’s disease gene homologue. Nat. Genet. 11, 155–163. doi:
10.1038/ng1095-155
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Kerschbamer and Biagioli. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Neuroscience | www.frontiersin.org 5 January 2016 | Volume 9 | Article 509
